Pourreau CN - Search Results

1

Interleukin-2 induces chemotactic deficiency in patients with onco hematologic malignancies and autologous bone marrow transplantation.

Stoppa AM, Fossat C, Blaise D, Viens P, Brandely M, Pourreau CN, Sainty D, Novakovitch G, Miquel M, Juhan-Vague I, et al. Stoppa AM, et al. Among authors: pourreau cn. Eur Cytokine Netw. 1991 Aug-Sep;2(4):231-7. Eur Cytokine Netw. 1991. PMID: 1661618

2

Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation.

Blaise D, Olive D, Stoppa AM, Viens P, Pourreau C, Lopez M, Attal M, Jasmin C, Monges G, Mawas C, et al. Blaise D, et al. Blood. 1990 Sep 15;76(6):1092-7. Blood. 1990. PMID: 2400805 Free article.

3

Recombinant interleukin-2 (rIL-2) after autologous bone marrow transplantation (BMT): a pilot study in 19 patients.

Blaise D, Viens P, Olive D, Stoppa AM, Gabert J, Pourreau CN, Attal M, Gaspard MH, Mannoni P, Jasmin C, et al. Blaise D, et al. Among authors: pourreau cn. Eur Cytokine Netw. 1991 Mar-Apr;2(2):121-9. Eur Cytokine Netw. 1991. PMID: 1813015 Clinical Trial.

4

Intravenous interleukin-2 just after high dose BCNU and autologous bone marrow transplantation. Report of a multicentric French pilot study.

Negrier S, Ranchere JY, Philip I, Merrouche Y, Biron P, Blaise D, Attal M, Rebattu P, Clavel M, Pourreau C, et al. Negrier S, et al. Bone Marrow Transplant. 1991 Oct;8(4):259-64. Bone Marrow Transplant. 1991. PMID: 1756323 Clinical Trial.

5

Phase I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancer.

Negrier MS, Pourreau CN, Palmer PA, Ranchere JY, Mercatello A, Viens P, Blaise D, Jasmin C, Misset JL, Franks CR, et al. Negrier MS, et al. Among authors: pourreau cn. J Immunother (1991). 1992 Feb;11(2):93-102. doi: 10.1097/00002371-199202000-00003. J Immunother (1991). 1992. PMID: 1571336

6

Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells.

Blancher A, Roubinet F, Grancher AS, Tremoulet M, Bonaté A, Delisle MB, Calot JP, Pourreau C, Franks C, Ducos J, et al. Blancher A, et al. Eur Cytokine Netw. 1993 Sep-Oct;4(5):331-41. Eur Cytokine Netw. 1993. PMID: 8117934 Clinical Trial.

7

Recombinant interleukin-2 continuous infusion in ovarian cancer patients with minimal residual disease at second-look.

Benedetti Panici P, Scambia G, Greggi S, Di Roberto P, Ragusa G, Perrone L, Sonsini C, Rumi C, Pourreau C, Palmer P, et al. Benedetti Panici P, et al. Cancer Treat Rev. 1989 Jun;16 Suppl A:123-7. doi: 10.1016/0305-7372(89)90032-7. Cancer Treat Rev. 1989. PMID: 2788502

8

Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma.

Palmer PA, Vinke J, Evers P, Pourreau C, Oskam R, Roest G, Vlems F, Becker L, Loriaux E, Franks CR. Palmer PA, et al. Eur J Cancer. 1992;28A(6-7):1038-44. doi: 10.1016/0959-8049(92)90450-g. Eur J Cancer. 1992. PMID: 1627369

9

Does Aeromonas salmonicida affect the immune system of carp, Cyprinus carpio L.?

Pourreau CN, Evenberg D, de Raadt WM, van Mechelen JA, van Muiswinkel WB. Pourreau CN, et al. Vet Immunol Immunopathol. 1986 Jun;12(1-4):331-8. doi: 10.1016/0165-2427(86)90137-6. Vet Immunol Immunopathol. 1986. PMID: 3765353

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9 results

Search Page

Filters